A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.
Six hundred forty-one dogs with clinical signs consistent with canine cognitive dysfunction syndrome (CDS) were treated orally with selegiline hydrochloride at 0.5 to 1.0 mg/kg once daily for 60 days. Response to selegiline treatment on days 30 and 60 were similar. On day 60, 77.2% of dogs showed an overall improvement; response to treatment by clinical sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members). All dogs enrolled in the study were monitored for possible adverse events; diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%) were noted most frequently. Results of this study indicate the majority of the dogs with CDS responded to treatment with Anipryl by day 30.
Campbell
S
S
Companion Animal Technical Services, Pfizer Animal Health, Exton, PA 19341, USA.
Trettien
A
A
Kozan
B
B
D000375:Aging; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008297:Male; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D012642:Selegiline